We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

RABIES ANTISERUM MARKET ANALYSIS

Rabies Antiserum Market, By Type (Monoclonal Antibodies (mAbs), Polyclonal Antibodies), By Application (Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Nov 2023
  • Code : CMI5711
  • Pages :155
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Rabies Antiserum MarketSize and Trends

The global rabies antiserum market size was valued at USD 1.24 billion in 2023. The market is projected to grow at a CAGR of 3.3% from 2023 to 2030, resulting in an estimated market size of USD 1.56 billion by the end of 2030.

Fig 1. Global Rabies Antiserum Market Share (%) by Region, 2023

Fig 2. Global Rabies Antiserum Market Share (%) by Type, 2023

Rabies Antiserum Market Drivers:

  • Increasing prevalence of rabies: Rabies is a serious and life-threatening disease that is prevalent in many parts of the world, particularly in developing countries. This has led to a growing demand for effective treatment options, such as antiserum. According to the data by the Centers for Disease Control and Prevention, each year, rabies causes approximately 59,000 deaths worldwide.
  • Rising awareness about rabies: Governments, NGOs, and other organizations are increasingly raising awareness about the dangers of rabies and the importance of prevention and treatment. This is driving demand for antiserum and other rabies treatments.
  • Availability of advanced treatment options: The development of advanced treatment options, such as monoclonal antibodies, has improved the effectiveness of rabies antiserum and is driving demand for these products. For instance, according to a study published in February 2022, significant advancements have been achieved in the field of post-exposure prophylaxis for rabies, transitioning from polyclonal antibodies in serum to monoclonal antibodies produced by hybridomas. Additionally, there has been notable progress in shifting from murine monoclonal antibodies to human monoclonal antibodies. Clinical trials have provided confirmation of the effectiveness of cocktails for neutralizing monoclonal antibodies.
  • Government initiatives: Many governments are implementing initiatives to control the spread of rabies and improve access to healthcare in developing countries. This is driving demand for antiserum and other rabies treatments in these regions.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.